Aura Biosciences Names Anthony Gibney Chief Financial, Business Officer

Dow Jones

May 15, 2025

By Colin Kellaher

Aura Biosciences has named Anthony Gibney as the clinical-stage biotechnology company's new chief financial and business officer.

Aura on Thursday said Gibney, 54 years old, joined the Boston company as a senior finance and strategy adviser in March.

The company said Gibney will receive an annual base salary of $525,000 and an annual bonus with a target of 45% of his base pay.

Amy Elazzouzi, Aura's senior vice president of finance, has been serving as interim chief financial officer since Julie Feder left the company last year. Aura said Elazzouzi will no longer serve as its principal financial officer but will remain principal accounting officer.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 15, 2025 07:55 ET (11:55 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535844852"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535844852\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535844852?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535844852","market":"sg","top_or_hot":-1,"title":"Aura Biosciences Names Anthony Gibney Chief Financial, Business Officer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Aura Biosciences has named Anthony Gibney as the clinical-stage biotechnology company's new chief financial and business officer. \n</p>\n<p>\n  Aura on Thursday said Gibney, 54 years old, joined the Boston company as a senior finance and strategy adviser in March. \n</p>\n<p>\n  The company said Gibney will receive an annual base salary of $525,000 and an annual bonus with a target of 45% of his base pay. \n</p>\n<p>\n  Amy Elazzouzi, Aura's senior vice president of finance, has been serving as interim chief financial officer since Julie Feder left the company last year. Aura said Elazzouzi will no longer serve as its principal financial officer but will remain principal accounting officer. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2025 07:55 ET (11:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aura Biosciences Names Anthony Gibney Chief Financial, Business Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAura Biosciences Names Anthony Gibney Chief Financial, Business Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-15 19:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Aura Biosciences has named Anthony Gibney as the clinical-stage biotechnology company's new chief financial and business officer. \n</p>\n<p>\n  Aura on Thursday said Gibney, 54 years old, joined the Boston company as a senior finance and strategy adviser in March. \n</p>\n<p>\n  The company said Gibney will receive an annual base salary of $525,000 and an annual bonus with a target of 45% of his base pay. \n</p>\n<p>\n  Amy Elazzouzi, Aura's senior vice president of finance, has been serving as interim chief financial officer since Julie Feder left the company last year. Aura said Elazzouzi will no longer serve as its principal financial officer but will remain principal accounting officer. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 15, 2025 07:55 ET (11:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535844852","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535844852","pubTimestamp":1747310100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aura Biosciences has named Anthony Gibney as the clinical-stage biotechnology company's new chief financial and business officer.Aura on Thursday said Gibney, 54 years old, joined the Boston company as a senior finance and strategy adviser in March.The company said Gibney will receive an annual base salary of $525,000 and an annual bonus with a target of 45% of his base pay.Amy Elazzouzi, Aura's senior vice president of finance, has been serving as interim chief financial officer since Julie Feder left the company last year. Aura said Elazzouzi will no longer serve as its principal financial officer but will remain principal accounting officer.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AURA":"Aura Biosciences, Inc."},"translate_title":"Aura Biosciences任命Anthony Gibney为首席财务、商务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AURA":1},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Aura Biosciences has named Anthony Gibney as the clinical-stage biotechnology company's new chief financial and business officer. \n\n\n  Aura on Thursday said Gibney, 54 years old, joined the Boston company as a senior finance and strategy adviser in March. \n\n\n  The company said Gibney will receive an annual base salary of $525,000 and an annual bonus with a target of 45% of his base pay. \n\n\n  Amy Elazzouzi, Aura's senior vice president of finance, has been serving as interim chief financial officer since Julie Feder left the company last year. Aura said Elazzouzi will no longer serve as its principal financial officer but will remain principal accounting officer. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2025 07:55 ET (11:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}